Evidence map›Paper›PMID 39870910›Full record

ArticleAnnals of hematology2025

Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma.

Yoshikazu Utsu, Yuki Isono, Shin-Ichi Masuda, Hironori Arai, Sonoko Shimoji, Rena Matsumoto, Takafumi Tsushima, Kazusuke Tanaka, Kosuke Matsuo, Chiharu Kimeda and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yoshikazu UtsuDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan. yutsu@naritasekijyuji.jp.ORCID http://orcid.org/0000-0002-3836-3216
Yuki IsonoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Shin-Ichi MasudaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Hironori AraiDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Sonoko ShimojiDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Rena MatsumotoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Takafumi TsushimaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Kazusuke TanakaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Kosuke MatsuoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Chiharu KimedaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Shiho KonnoDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Yudai YanoDepartment of Medical Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Nobuhiko KuramotoDepartment of Nephrology, Japanese Red Cross Narita Hospital, Narita, Japan.
Nobuyuki AotsukaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal impairment is reported in 20%-50% of patients with newly diagnosed multiple myeloma and is known as a poor prognostic factor. Although several studies have demonstrated that treatment with novel antimyeloma agents improves renal impairment and myeloma itself, the time-dependent clinical course of recovery of renal function has not been extensively studied. We retrospectively collected the data of characteristics and outcomes in consecutive unselected patients diagnosed with and treated for symptomatic multiple myeloma between January 2015 and December 2022, and extracted and analyzed the cases with renal impairment. Among 234 patients with multiple myeloma, 67 (28.6%) had renal impairment (estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m

Indexed as

Multiple MyelomaRecovery of FunctionRenal InsufficiencyAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibCalciumFemaleGlomerular Filtration RateHumansMaleMiddle AgedRetrospective StudiesTime FactorsBortezomibCalciumeGFRMultiple myelomaMyeloma kidneyRenal functionRenal impairment

Identifiers

PMID39870910
PMCPMC11868295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.